Concepedia

Author

Olivia M Dong

University of North Carolina at Chapel HillORCID

Also Known As

Dong, Olivia, O. Dong, Olivia Dong, Olivia M Dong, Olivia M. Dong

31

Publications

327

Citations

11

H-Index

32

Concepts

All Affiliations

University of North Carolina at Chapel HillDuke UniversityDurham VA Health Care SystemGTx (United States)VA Boston Healthcare System
OM

About

Olivia M Dong is an author at University of North Carolina at Chapel Hill specializing in medicine, precision medicine, and genomic medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

47

2

Health Sciences

1

1

12

3

Public Health

1

1

25

4

Clinical Sciences

1

1

25

5

Genetic Medicine

1

1

10

Olivia M Dong

×

13

Publications

246

Citations

10

H-Index

YearCitations

Implementing Clinical Pharmacogenomics in the Classroom: Student Pharmacist Impressions of an Educational Intervention Including Personal Genotyping

Amber Frick, Cristina S. Benton, Oscar Suzuki,

Pharmacy

2018

37

Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention

Olivia M Dong, Stephanie B. Wheeler, Gracelyn Cruden,

Value in Health

2019

36

<i>CYP2C19</i> -Guided Antiplatelet Therapy: A Cost–Effectiveness Analysis of 30-Day and 1-Year Outcomes Following Percutaneous Coronary Intervention

Mrudula Borse, Olivia M Dong, Melissa J. Polasek,

Pharmacogenomics

2017

35

Strategies to Integrate Genomic Medicine into Clinical Care: Evidence from the IGNITE Network

Nina Sperber, Olivia M Dong, Megan C. Roberts,

Journal of Personalized Medicine

2021

25

Projected Impact of a Multigene Pharmacogenetic Test to Optimize Medication Prescribing in Cardiovascular Patients

Olivia M Dong, Amy Li, Oscar Suzuki,

Pharmacogenomics

2018

18

Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) Clinical Program at Initial Test Sites

Olivia M Dong, Megan C. Roberts, R. Ryanne Wu,

Pharmacogenomics

2021

18

Medical Policy Determinations for Pharmacogenetic Tests Among US Health Plans

Jai N. Patel, Lena Chaihorsky, Olivia M Dong,

The American Journal of Managed Care

2025

13

Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma

Olivia M Dong, Pradeep Poonnen, David Winski,

Value in Health

2021

12

Cost-effectiveness of<i>CYP2C19</i>-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes

Olivia M Dong, Kevin A. Friede, Catherine Chanfreau‐Coffinier,

European Heart Journal - Quality of Care and Clinical Outcomes

2022

11

Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States

William L. Herring, Meghan Gallagher, Nirmish Shah,

PharmacoEconomics

2024

11

Page 1